ACE2 Human Recombinant Protein (Angiotensin Converting Enzyme 2)
CAT#: TP724618
Recombinant Human ACE2 Protein (C-hFc)
|
Need it in bulk or customized? Get a free quote |
CNY 3140.00
货期*
5周
规格
Product images
推荐一起购买 (1)
ACE2 mouse monoclonal antibody, clone OTI4D2 (formerly 4D2)
CNY 1999.00
CNY 2700.00
Specifications
| Product Data | |
| Species | Human |
| Protein Source | HEK293 |
| Expression cDNA Clone or AA Sequence |
18-740
|
| Tag | C-hFc |
| Buffer | Lyophilized from a 0.2 um filtered solution of PBS, pH7.4 |
| Note | Recombinant Human ACE2 Protein is produced by HEK293. The target gene encoding 18-740 is expressed with a hFc tag at the C terminus. |
| Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-5 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Stability | 12 months from date of despatch |
| Reference Data | |
| Locus ID | 59272 |
| UniProt ID | Q9BYF1 |
| Synonyms | Angiotensin-Converting Enzyme 2; ACE-Related Carboxypeptidase; Angiotensin-ConvertingEnzyme Homolog; ACEH; Metalloprotease MPROT15; ACE2 |
| Summary | Angiotensin-Converting Enzyme 2 (ACE-2) is an integral membrane protein and a zinc metalloprotease of the ACE family, the ACE family includes somatic and germinal ACE. ACE-2 cleaves angiotensin I and II as a carboxypeptidase and converts angiotensin I to angiotensin 1-9, and angiotensin II to angiotensin 1-7. ACE-2 is also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. ACE-2 can be high expressed in testis, kidney and heart, in colon, small intestine and ovary at moderate levels. Captopril and lisinopril as the classical ACE inhibitor do not inhibit ACE-2 activity. ACE-2 may play an important role in regulating the heart function. |
| Protein Families | Druggable Genome, Secreted Protein, Transmembrane |
| Protein Pathways | Renin-angiotensin system |
Documents
| FAQs |
| SDS |
其它Angiotensin Converting Enzyme 2产品
Customer
Reviews
Loading...
